Research progress of the application of mesenchymal stem cells in chronic inflammatory systemic diseases

Fangfang Huang1, Erick Thokerunga1, Fajian He2, Xinyu Zhu1, Zi Wang1 and Jiancheng Tu1*

Abstract
Chronic inflammatory systemic diseases are the result of the body's immune imbalance, with a long course and recurring episodes. Immunosuppressants are the main treatment, but not all patients respond well to it. Being capable of both self-renewal and differentiation into multiple tissue cells and low immunogenicity, mesenchymal stem cell is a promising treatment for chronic inflammatory systemic diseases. In this article, we describe the research progress and clinical application of mesenchymal stem cells in chronic inflammatory systemic diseases and look for influencing factors and biomarkers that can predict the outcome of patient with mesenchymal stem cell transplantation.

Keywords: Mesenchymal stem cells, Prognosis, Biomarkers, Rheumatoid arthritis, Systemic lupus erythematosus, Inflammatory bowel disease

Background
Chronic inflammatory systemic disease (CID) is a collective term for diseases that are characterized by prolonged inflammation lasting several months to years. They include rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, etc. Due to a damaged inflammation self-regulatory mechanism, patients with CID have repeated episodes of inflammation, resulting in simultaneous destruction and healing of tissues at the inflammation site [1]. Corticosteroids, immunosuppressants and monoclonal antibodies are used to treat immune diseases, but drug resistance and adverse reactions limit their use. As stem cell therapy becomes more popular due to their ease to obtain and lesser ethical requirements.

The International Society for Cell Therapy defines mesenchymal stem cells (MSC) as non-hematopoietic stem cells that are: (1) plastic adherent in standard culture conditions; (2) express CD73, CD90 and CD105 but lack CD11b, CD14, CD34, CD45 CD19 or CD79α and HLA-DR antigens, and (3) differentiate into osteoblasts, adipocytes and chondroblast in vitro [2]. Mesenchymal stem cells are found in the bone marrow, umbilical cord blood, the placenta, adipose tissues, amniotic fluids, dental tissues, skin, hair follicles and tonsils [3].

Mesenchymal stem cells are pluripotent progenitor cells capable of migration to injury and tumor sites, self-renewal and differentiation into multiple tissues. They are strong immune modulators producing immunomodulatory molecules such as indoleamine 2,3-dioxygenase (IDO) [4], TGF-β [5], PGE2 [6] and NO [7], or acting directly through PDL-1/PD-1 [8], PDL-1/B7-H1 [9] or ICAM-1/LFA-1 [10] ligand to influence immune cells' proliferation, differentiation, maturation and polarization [11, 12]. The immunosuppressive mechanisms of MSC are shown in Fig. 1.

IFN-γ, a type II interferon, enhances both the immunosuppressive and migratory ability of MSC [13]. The IFN-γ produced by T cells promotes the expression of IDO in...
MSC through IFNGR1/STAT and p38-MAPK signaling [4, 14, 15]. Two types of IDO exist, IDO1 and IDO2. Autoreactive B cell responses are mediated by IDO2, while autoreactive T cell responses are indirectly affected by IDO1 expression [16]. IDO depletes tryptophan in local tissue microenvironments and generates kynurenines a immunoregulatory catabolites, thus activate GCN2 signaling pathway and mTOR signaling pathway [17, 18] and down-regulates the expression and activation of Vav1 protein [19]. This induces the conversion of naive CD4(+)CD25(−) T cells into highly suppressive Treg; therefore, the modulation of IDO activity favors the interconversion between Treg cells and Th17 inflammatory cells [20]. Certain studies, however, show that IDO inhibitors do not have effects on Treg and Th17 cells [21]. IDO also induces increased PDL-1 expression and upregulates different immunomodulatory exosome-derived miRNAs that are involved in the control of both T cell activation/anergy and monocyte differentiation, resulting into inhibition of T cell activity, induction of M2-like phenotypes in monocytes, and increased production of IL-10 [4, 8].

TNF-α could enhance the expression of IFN-γ receptor (IFN-γR) via NF-κB signaling, in turn, enhanced responsiveness of MSC to IFN-γ stimulation activated STAT5 and p38-MAPK signaling [14]. However, studies have shown that TNF-α sometimes inhibits the immunosuppressive ability of MSC by enhancing the expression of costimulatory molecules ICOSL and HLA-DR on the surface of dendritic cells, while reducing the expression of PDL-1/PD-1, IL-10 and TGF-β [22]. Transforming growth factor beta (TGF-β) is a crucial cytokine for immune response regulation [23]. MSC secreted TGF-β skews macrophage polarization toward the M2-like phenotype through modulating the Akt/FoxO1 pathway, thus improving their phagocytic ability. It is also believed to up-regulate Treg cells [5, 21]. Phagocytosed apoptotic cells in turn release COX2 that promote MSC’s secretion of PGE2 resulting into down regulation of Th17 cells [6, 21]. Nitric oxide (NO) from MSCs is involved in the

![Diagram](image-url)
suppression of STAT5 phosphorylation and T follicular helper (Tfh) cell expansion [7, 24].

Recently, B cells have become a major target for the treatment of immune disorders. Results of MSC and B cell co-cultivation show that MSCs support static B cell survival but do not induce B cell proliferation. In addition, they regulate B-cell function through directly promoting B cells differentiation into IL-10 producing CD19+CD24hiCD38hi B cells, known as Brag cells; or by suppressing B cells via T helper or Tfh cells through repressing the differentiation of naive CD4(+) T cells into Tfh cells; or through releasing IDO and iNOS [7, 25–27].

In addition, studies have found that exosomes derived from mesenchymal stem cells also play an important role in mesenchymal stem cell therapy. A study of intervertebral disc degeneration found out that BM-MSC-derived exosomes promote the growth and survival of host cells. At the same time, nucleus pulposus cells-derived exosomes promoted BM-MSC migration and induced its differentiation to a nucleus pulposus-like phenotype [28]. MSC-derived exosomes also promote macrophages switch to M2 phenotype [29]. Interestingly, MSC can mischievously transfer its own mitochondria into Th17 cells and decrease their activity by increasing their oxygen consumption [30]. In diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), where the phenotype and function of MSC of the patients differ from those of healthy ones, MSC can be targets for treatment [31–34].

MSCs are currently the most widely used stem cells in clinical practice despite the inconsistent clinical outcomes due to the difference in sources, dosages and timing [35]. This review seeks to answer the questions of which type of patients are suitable for MSC therapy, and what indicators can be used to monitor effectiveness of the treatment. Bone marrow and adipose tissues derived MSCs are popularly used, only a handful of studies have reported the use of placenta derived MSC. Studies also show that MSC pretreatment with IFN-γ or combined with IL-4/IL-25 has a better therapeutic effect [36–38]. In vitro studies have shown that highly inflammatory synovial fluid (SF) could better stimulate the proliferation and immunosuppressive ability of MSC [39], suggesting that MSC can achieve the best effect when the inflammatory factors in the patient’s body are increased or right in the course of the disease. MSC delivery methods include systemic delivery and local delivery. Intra-venous delivery is the most commonly used route of administration [40]. However, MSCs injected intravenously are sometimes enriched in the lung and spleen tissues, where they are easily recognized and eliminated by immune cells, leaving only a small number to reach the targeted organs [41]. Most of the current clinical research patients receive a single intravenous infusion of 1 × 10^7 cells/kg, and only a small part of patients will undergo two to three infusions. The local injection dose of colon tissue is 1 × 10^7–1.2 × 10^8 cells. Furthermore, a few dose-escalating trials have found no dose–response relationship [42, 43]. As shown in Table 1, intravenous infusion of MSC is relatively safe, and serious adverse reactions related to treatment are rare. However, some adverse events occasionally occur. Common adverse events in clinical studies include leukopenia, pneumonia, subcutaneous abscess, infection and fever. In refractory Crohn’s disease, the incidence of adverse reactions of local MSC transplantation is relatively high, including anal abscess, fever, fever, fistula or anal bleeding, colon infection and so on.

Given that the traditional managements of CID (anti-inflammatory drugs/hormone therapy) do not benefit all patients, it is no surprise that MSC is being explored as a possible therapeutic alternative. However, we still know very little known about what happens when MSC are injected into the patient. This has made it difficult to associate with certainty their action to the healing of chronic inflammatory processes. Identification of biomarkers that are associated with the action of MSC and their healing property on CID is extremely vital. This will enable objective assessment of the effectiveness of MSC therapy in chronic inflammatory systemic diseases and monitoring of any side effects thereof. In this mini review, we discuss the progress made in the mesenchymal stem cell therapy of Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Inflammatory Bowel Disease (IBD) and explore the clinically significant biomarkers that are associated with their prognosis.

**Rheumatoid arthritis (RA)**

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by synovial hyperplasia and edema. Its sequelae involves inflammatory cell infiltration of the synovium, cartilage damage and bone erosion due to the chronic inflammatory process [44]. A major factor in RA pathogenesis is the inflammation of intra-joint connective tissue called synovium. The inflammatory process is composed mostly of fibroblast-like synoviocytes (FLS), macrophages and infiltrating lymphocytes [45], with the macrophages maintained in a delicate back and forth transition between pro-inflammatory M1 and anti-inflammatory M2 phenotypes [46]. Bone destruction is closely related to the imbalance between osteoclasts and osteoblasts. Intracellular signaling pathways such as MAPK, Wnt, Hedgehog (Hh), Notch, Akt/mTOR, TGF-β/BMP are involved in regulating the proliferation and differentiation of osteoblasts. Highly inflammatory synovial fluid inhibits osteoblast
Table 1: Trials about MSCs in RA, SLE, IBD

| MSC source | No. of patients | Dosage and usage | Result | Adverse events | Indicatora | References |
|------------|-----------------|------------------|--------|----------------|------------|------------|
| hUC-MSCs   | 63 RA           | $1 \times 10^6$ cells/kg intravenous infusion | 53.3% (MSCT), 93.3% (MSCT+IFN-γ) in 3-month follow-up | No safety issues in 1-year follow-up | HAQ, DAS28, ESR, CRP, RF, Tregs/Th17 | [37] |
| UCMSCs     | 105 RA          | $1 \times 10^6$ cells/kg intravenous infusion | 53.85% in 3-month follow-up, last for 48 weeks | No serious adverse events | HAQ, DAS28, platelet, Treg/Th17, IL-6, TNF-α, anti-CCP, RF, IL-10, IL-8, hemoglobin, albumin, IL-10, IFN-γ | [58] |
| adMSCs     | 110 CIA animal model | $1 \times 10^5$/mouse intravenous infusion (tail vein) | 14 days | GM-CSF+CD4+T, Lag3+Tr1 Tregs, Tr1, (Tregs+Tr1)/GM-CSF+CD4+T | | [64] |
| hUCB-MSCs  | 9 RA            | $2.5 \times 10^7, 5 \times 10^7, 1 \times 10^8$ cells intravenous infusion | 4 weeks | no short-term safety concerns | DAS28, IL-1β, IL-6, IL-8, TNF-α | [60] |
| UC-MSC     | 64 RA           | $4 \times 10^7$ cells/RA intravenous injection | 1 year | 4% showed flu-like symptoms | HAQ, DAS28, ESR, CRP, RF, globulin, Platelet (1 year, 3 year) anti-CCP (3 year) TP, ALB, WB, MCV | [61] |
| BMSC       | 30 RA           | $4 \times 10^7$ cells/joint intra-articular knee implantation | 12 months | pain/articular swelling and other minor adverse events | WOMAC, time to jelling and pain-free walking distance, MTX and prednisolone intake DAS28, ESR, CRP, MRI imaging score | [62] |
| BM-MSCs/UC-MSC | 81 SLE     | $1 \times 10^6$ cells/kg intravenous infusion | 34% (remission for 5 years) 84% (survival rate for 5 years) 24% (relapse within 5 years) | renal dysfunction, diarrhea, infection, myocardial infarction, diabetes | proteinuria C4, serum urea nitrogen, creatinine, and uric acid albumin, C3, WBC, hemoglobin, platelet | [59] |
| BM-/UC-MSCs | 69 SLE         | $1 \times 10^6$ cells/kg intravenous infusion | 58% (LDA) 23% (remission) | | | [80] |
| hUC-MSC    | 18 LN           | $2 \times 10^6$ cells intravenous infusion | 75% (remission) | leucopenia, pneumonia, subcutaneous abscess | SLEDAI, Th17 WBC, platelet, Hb, Tregs, Treg/Th17 | [79] |
| BM-/UC-MSCs | 35 SLE         | $1 \times 10^6$ cells/kg intravenous infusion | 24 months | no adverse events | | | [79] |
| MSC source       | No. of patients | Dosage and usage                                      | Result                                                                 | Adverse events                                                                 | Indicator(s)                                                                 | References |
|------------------|-----------------|-------------------------------------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------|
| hBM-MSCs         | NZB/W mice      | $1 \times 10^6$ cells/mouse/injection at 17, 19, and 21 weeks of age | etro-orbital injection of the venous sinus                          | anti-dsDNA, urinary albumin, Th 1Th2, Th17, Tregs                              |                                                                                   | [27]       |
| UC-MSCs          | 30SLE           | $1 \times 10^6$ cells/kg intravenous infusion         | 12 months                                                             | Th17,IL-17, TNF-α, IL-6, IL-17A, Treg, Foxp3, TGF-β                          | F4/80+, CD11b+macrophages, CD103+monocytes, CD3+T cells, CD4+T cells            | [21]       |
| adMSC/IMSC       | DSS             | $1 \times 10^6$ cells at 10, 13, 16 day tail vein infusion |                                                                      | $\text{Ki-67}^+$ intestinal epithelial cells, $\text{CD31}^+$ endothelium, $\text{FOXP3}^+$ Tregs (in tissue) | ROS, lipid MDA formation, INF-γ, TNF-α, IL-4, CD8, p-NF-kB, type I collagen, CD4, SOD2, Catalase, SOD1 (in tissue) | [99]       |
| hBM-MSCs         | IL-10$^-/-$ mice | $5 \times 10^5$ cells 0, 1 week tail vein infusion |                                                                      | IL 17A$^+$ Th17, IFN-$\gamma^+$ Th1 FOXP3+Tregs, IL4+Th2 (in PB, tissue)      | $\text{Ki-67}^+$ intestinal epithelial cells, $\text{LGR5}^+$ intestinal stem cells, $\text{CD31}^+$ endothelium (in tissue) | [38]       |
| hBM-MSCs         | DSS             | $5 \times 10^6$ cells 1, 2, 3 day tail vein infusion |                                                                      | IL-6, TNF-α, IFN-$\gamma$, IL-17A IL-10 (in tissue)                         |                                                                                  | [13]       |
| IBM-MSCs         | DSS             | $1 \times 10^6$ cells 7 day injected intraperitoneally |                                                                      | IL-6, TNF-α, IFN-$\gamma$, IL-17A IL-10 (in tissue)                         |                                                                                  | [13]       |
| IBM-MSCs         | TNBS            | $1 \times 10^6$ cells 7 day injected intraperitoneally |                                                                      | SAA, TNF-α, IL-6, IFN-$\gamma$, IL-17A IL-10 (in tissue)                    |                                                                                  | [13]       |
| adMSCs           | TNBS            | $1 \times 10^6$ cells 1, 2 day injected intraperitoneally |                                                                      | TNF-α, IFN-$\gamma$, IL-6, IL-1β, IL-12, RANTES, macrophage inhibitory protein 2, Th1 IL-10, Treg (in tissue) |                                                                                  | [100]      |
Table 1 (continued)

| MSC source | No. of patients | Dosage and usage | Result | Adverse events | Indicator | References |
|------------|----------------|------------------|--------|----------------|----------|-----------|
| adMSCs     | TNBS           | 3 to 5 x 10^6 cells injected intraperitoneally |        | TNF-α, IL-12, IL-6, IL-23, IL-21, IFN-γ, IL-17A, IL-10, TGF-β | (in serum) | [101]     |
|            |                |                  |        | IL-17A         | MSo, PDAl |           |
|            |                |                  |        | Th1, Th17      | MSo, PDAl |           |
|            |                |                  |        | Th2            | MSo, PDAl |           |
|            |                |                  |        | CD'S+BReg      | MSo, PDAl |           |
|            |                |                  |        | IL-10, IFN-γ   | MSo, PDAl |           |
|            |                |                  |        | ROS            | MSo, PDAl |           |
|            |                |                  |        | IL-17, TGF-β   | MSo, PDAl |           |
|            |                |                  |        | (in spleen, MLN)| MSo, PDAl |           |
| P-MSCs     | EF             | 1 x 10^6 cells intralesional injection |        | IL-1β, IL-6, TNF-α, IFN-γ, ROS | IL-10, TGF-β, VEGF, Ang-2 | [98]     |
| adMSCs     | 24 CD w/ fistulas | 2 x 10^7 cells intralesional injection | At 24 weeks 69.2% (response) 56.3% (some fistulas close) 30% (all fistula close) | anal abscess (12.5%) pyrexia (4.17%) uterine leiomyoma (4.17%) | MSo, PDAl | [103] |
| BM-MSCs    | 15 CD w/ fistulas | 1 x 10^7, 3 x 10^7, 9 x 10^7 cells intralesional injection | At 12 weeks 40.0%, 80.0%, 20.0% (all fistula close) | Fever at 24 weeks 80.0% (1 x 10^7) follow-up by 4 years 63.0%, 100%, 43.0% (closed fistula) | PDAl, IL-8, IL-1β, IL-6 | [42, 102] |
|            |                |                  |        | IL-10, TNF, IL-12p70 (cannot be detected) | PDAl, IL-8, IL-1β, IL-6 | [42, 102] |
| autologous MSC | 12 CD w/ fistulas | 2 x 10^7 cells intralesional injection | At 24 weeks 83% (all fistula close) | no related adverse events | PDAI | [105] |
| autologous ADSVF | 10 CD w/ fistulas | intralesional injection | At 12 weeks 20% (combined remission), 70% (clinical response) | Flares at 48 weeks 60% (combined remission), 80% (clinical response) | PDAI | [106] |
| adMSCs     | 212 CD w/ fistulas | 1.2 x 10^8 cells intralesional injection | 50% (remission) 17% (adverse events) | anal abscess proctalgia | PDAI | [104] |
| BM-MSCs    | 12 CD          | 2 x 10^6, 5 x 10^6, 10 x 10^6 cells/kg intravenous infusion | 12-weeks | acute appendicitis, C. difficile colitis | IBDQ, CDAI, time to combined remission, relapse, time to relapse, van Assche score | [43] |
| UC-MSCs    | 82 CDI 220–450 | 1 x 10^6 cells/kg intravenous infusion | No patient achieved complete remission (CDAI < 150) | upper respiratory tract infection | CDAI, HBI, and corticosteroid dosage | [107] |

~ Blood cell count, Liver and renal function
Table 1 (continued)

| MSC source | No. of patients | Dosage and usage | Result | Adverse events | Indicator* | References |
|------------|----------------|------------------|--------|----------------|------------|------------|
| BM-MSCs    | 13 CDAI 220–450 | 1.5 to 2.0 x 10^6 cells/kg at weeks 0 and 4 intravenous infusion | At week 12  
15.4% (clinical response)  
7.7% (remission) | no related adverse events | CDAI, CRP, FC, Treg, CD4+T, CD8+T, IgA/G/M, NK%, NKT% | [96] |

Bold indicates a decrease, italic indicates no significant change, and bold italic indicates an increase
proliferation [47]. Osteoclastogenesis needs two factors, macrophage colony-stimulating factor (M-CSF) for proliferation and survival, and receptor activator of NF-κB ligand (RANKL) for differentiation and function [48]. RANKL is a TNF superfamily member and an essential mediator of osteoclastogenesis, produced by osteoblasts, synovial fibroblasts and activated T cells [48]. Only Th17 has been confirmed to be associated with proliferation and differentiation of osteoclasts in RA, thus promoting bone destruction [49].

Patient Activity Scale (PAS) or PASII, Routine Assessment of Patient Index Data 3 (RAPID-3), Clinical Disease Activity Index (CDAI), Disease Activity Score with 28-joint counts (ESR or CRP), Simplified Disease Activity Index (SDAI) are instruments to measure rheumatoid arthritis disease activity and to define remission [50]. RF (rheumatoid factor), ACPAs (anticitrullinated protein antibodies), ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) are used as RA classification criteria in clinical practice [51]. RA patients also present increase in other autoantibodies such as anti-carbamylated proteins, anti-peptidylarginine deiminase (PAD-4), anti-collagen type II, and anti-IgG hinge, as well as a variety of inflammatory factors, chemokines [52].

For RA disease, in addition to the immunosuppressive function of MSC, other therapeutic mechanisms of MSC have also been explored. Recent pre-clinical study has discovered that hUCB-MSCs can promote the transition of macrophages tilting the equilibrium toward the formation of M2-type cells by the tumor necrosis factor (TNF)-α-mediated activation of cyclooxygenase-2 and TNF-stimulated gene/protein 6 in hUCB-MSCs, a process that favors cartilage production and thus repair of inflammatory damages in RA [53]. In addition, MSC were observed in the cartilage tissue from day 11 and until 42 days after intravenous injection and differentiated into cartilage and osteoblasts via MAPK and Wnt signals [54–56], while inhibiting osteoclast formation via CD39-CD73-adenosine signals [57], thereby preventing bone destruction.

As a therapeutic agent, the combination of MSC with IFN-γ has been shown to significantly alleviate symptoms of arthritis in up to 93.3% of patients within 3 months, and no relapse within 1 year of follow-up [37]. It has been discovered that high concentrations of IFN-γ produced by T cells induce MSC to produce more indoleamine 2,3-dioxygenase (IDO), thereby enhancing MSC’s autoimmune regulation ability [15]. IFN-γ thus maybe a key moderator of MSC’s therapeutic function in RA patients whose serum level is directly associated with the RA patients’ response to MSC therapy. A study by Yang et al. [58] assessed possible serum biomarker for predicting the therapeutic effect of MSC therapy in rheumatoid arthritis (RA) patients and found out that MSCT resulted in a transient increase in serum IFN-γ (> 2 pg/ml), promoted an increase in IL-10 levels and the Treg/Th17 ratio, and decrease DAS28, the decreased value at the 12-week was closely related to the increase in IFN-γ level. In a work, a high level of serum IFN-γ before or transient rise in IFN-γ after mesenchymal stem cell transplantation is a positive predictor of RA remission.

A 5-year follow-up found that patients had 34% of remission, 84% of survival rate, and 24% of recurrence rate [59]. Intravenous MSC transplantation (MSCT) significantly decreased DAS28, HAQ, platelets, ESR, CRP, RF, prednisone dose, antinuclear antibody (ANA), cartilage oligomeric matrix protein (Comp), tissue inhibitor metalloproteinase-1 (Timp1), matrix metalloproteinase 1 (Mmp-1) and IL-1R, MCP-1, IL-6, TNF-α, increase hemoglobin, albumin, Treg/Th17 ratio, IL-10, IFN-γ, and the proportion of Low Disease Activity [36, 58, 60], while the result of IL-1β, IL-8, IL-2R, anti-CCP antibody, RF is inconsistent [60, 61]. Liver, kidney function and immunoglobulins levels from each patient were all within normal range before, 1 year and 3 years after UC-MSC treatment; HAQ and DAS28 continued to decrease at 3 years after treatment, suggesting the long-term efficacy of UC-MSC treatment [61]. 6.7% patients in the MSC group relapsed at the 24th week of follow-up accompanied by elevated levels of ESR and CRP [37]. However, improvement of WOMAC, VAS, time to jelling and pain-free walking distance could not be significantly sustained beyond 12 months, and the MRI imaging score of the knee did not reveal any improvement in some of the patients who received BMSCs by intra-articular knee implantation [62].

Recent data have identified that GM-CSF-expressing T cell is a unique T helper subset having critical roles in the pathogenesis of arthritis and other inflammatory diseases [63]. Lopez-Santalla et al. [64] conducted an experiment in arthritis mice to examine the modulation effect of MSC on GM-CSF CD4+T cells and Th17 cells. They observed a significant decrease in the severity of the arthritis shortly after injecting the mice with adipose-derived MSC. A further notable effect was the reduction in the number of pathogenic GM-CSF CD4+T cells in the spleen and peripheral blood, accompanied by an increase in the number of Treg and IL10+IL17−CD4+T cells in the draining lymph nodes [64]. It is clear that MSCT induces changes in different types of immune cells in peripheral blood and so the best option is to monitor a variety of immune cells at ago in order to accurately determine treatment outcomes following MSCT. Changes in the number of immune cells in the spleen, however, seem more accurate and should be explored further.
In RA, therefore, MSC combined with IFN-γ significantly alleviate symptoms of the disease with good long-term outlook (No relapse up to 1-year post treatment). Moreover, a high level of serum IFN-γ before or transient rise in IFN-γ after mesenchymal stem cell transplantation positively predicts good treatment outcome. MSC can reverse some of the clinical evaluation indicators of RA patients, such as DAS28, HAQ and immune markers, and reduce joint tissue damage markers, but the changes in autoantibodies after MSCT are not obvious. ESR and CRP are good biomarkers for monitoring MSCT therapy. Since immune markers are non-specific, monitoring a variety of them at once is a better indicator of prognosis and treatment outcome.

**Systemic lupus erythematosus (SLE)**

SLE is an autoimmune disease characterized by the destruction of the patient’s autoimmune tolerance, production of nuclear-antibodies and immune complexes, and disruption of multiple organ functions. 10% of SLE patients eventually develop lupus nephritis (LN), and only half of the LN patients recover [65]. The target for managing lupus is to improve patients’ long-term outcomes and quality of life, and so management plan is to treat the disease symptoms, prevent damage to other major organs and minimize drug side effects. The pathogenesis of SLE is multifactorial. Abnormal clearance of apoptotic cells is related to the beginning of SLE [66]. Autoantigens are released mainly from secondary necrotic cells because of a defective clearance of apoptotic cells or an inefficient degradation of DNA, and then, these autoantigens are presented by dendritic cells to autoreactive B cells, forming immune complexes (IC). Many patients with systemic autoimmune diseases including SLE have signs of aberrant production of type I interferon (IFN) and display an increased expression of IFN-inducible genes, and the clearance of antinuclear IC via Fc-gamma receptors is considered a central event in amplifying inflammatory immune responses in SLE [66, 67]. Excessive activation of B cells and the production of autoantibodies play an important role in SLE. Current studies have suggested that both impairments of Breg cell functions and expansions of autoreactive B subsets (Age-Associated B cell, inate-like B cells, plasma cells) lead to immune tolerance breakdown and autoimmune progression [68].

Diagnostic biomarkers frequently used in clinical practice include ANA, anti-dsDNA antibodies, anti-Sm, anti-cardiolipin, anti-β2-glycoprotein I, lupus anticoagulant, complement proteins C3 and C4(↓) [69]. SLE Disease Activity Index (SLEDAI), the dosage of immunosuppressive agents, anti-dsDNA antibodies, serum complement proteins C3 and C4 are usually applied to SLE assessment while creatinine clearance (↓), urine protein (↑), and lung volume (↓) are applied to organ function monitoring [70]. Potential biomarkers for lupus disease activity include anti-C1q antibodies, CBCAPs (RC4d, EC4d and EC3d), IFN-α and IFN-inducible genes, B-cell-activating factor (BAFF) or B-lymphocyte stimulator (BlyS), a proliferation inducing ligand (APRIL) [71]. CD4+ and CD8-T cell transcription signals, Treg, Tf (T peripheral helper) cells, IFN, cDNA, CTHRC1 (collagen triple helix repeat containing 1) are closely related to SLE outcome and SLEDAI [72–77].

Mesenchymal stem cell therapy (MSCT) is safe and results into long-term clinical remission in SLE patients. A five-year follow-up study found that 34% of patients with SLE had remission, 84% survival rate, and recurrence rate 24% post MSCT [59]. SLE Disease Activity Index (SLEDAI) scores decreased significantly, while albumin, complement C3, WBC, platelets, hemoglobin, lung volume and quality of life continued to improve during follow-up; dsDNA, ANA, proteinuria, serum urea nitrogen, creatinine levels decreased in 1 year after MSCT [59, 78]. The number of Treg, Treg/Th17 ratio, Foxp3 and TGF-β in the MSCT group increased, while Th17, IL-17 and TNF-α decreased significantly, and IL-6 and IL-17A had no changes [21, 79]. Pretreatment factors that can affect treatment efficacy are discussed by Wen et al. [80]. In a separate study, there was no difference in most of the above immune markers between the treatment and control group. SLEDAI score, blood cell count, serum albumin, proteinuria and Treg/Th17 percentages between those with or without cyclophosphamide (CYC) pretreatment, those infused with bone marrow- or umbilical cord-derived MSCs were similar between the two groups [78, 79]. Disease relapse was not correlated with age, disease duration, MSCs source, CYC pre-treatment, baseline SLEDAI score, or proteinuria levels [59]. It was, however, found that patients who had higher levels of baseline IFN-γ and lower levels of baseline IL-6 showed a good clinical response to MSCT; serum TNF-α, IL-17, TGF-β1, and IL-10 had no difference between MSCT responders and non-responders among these patients [81]. This result is consistent with those of MSCT of RA [58].

Studies show that MSCT patients with lupus nephritis cannot get a positive therapeutic effect compared to placebo group [82] and are likely to cause renal insufficiency [59]. At present, there is still a big controversy about the therapeutic effect of MSC on LN. Traditional biomarkers for LN include dsDNA, complement, proteinuria, and active deposits. New biomarkers include MCP-1, NGAL, CXCL-10, CXCL-16, IL-6, IL-17, VCAM, TGF in urine -β1 mRNA and L-PGDS. Chemokines and inflammatory factors can better predict LN [83]. The result of
a meta-analysis showed that the renal sclerosis score, ds-DNA, ANA, creatinine, urea nitrogen, proteinuria, IL-2, IL-12, IL-17 and IFN-γ cytokine levels of MSCT LN mice decreased, while IL-4, IL-6, IL-10, TGF-β, MCP-1, TNF-α cytokines and Th1, Th17, Treg cells are not significantly changed [84]. Th1 (CD4+CXCR5+PD-1+Tfh), CD4+CD44+CXCR5+PD-1+Tfh), B (GC B (B220+GL7+), PC (B22010 CD138+)) cells, which are associated with high concentrations of autoimmunity antibodies and LN, are decreased in animal model after MSCT. While administration of hBMSC in the middle of the clinical phase of the disease is believed to suppress auto-Ab production and prevent the occurrence of LN, but does not reverse the progression of an ongoing nephritis, revealing a new mechanism for MSC to treat LN [27].

MSCT can make SLE patients survive up to 85% in 5 years, and the clinical markers of patients continue to improve during the follow-up period. There is no difference in the treatment of patients with bone marrow- or umbilical cord-derived MSCs. However, the pre-MSCT state of patients may affect the efficacy of MSCT. Like RA, patients with higher levels of IFN-γ or lower levels of baseline IL-6 at baseline showed a good clinical response to MSCT, and administration of hBMSC midway through the course of the disease can slow down nephritis and prevent development of LN.

**Inflammatory bowel disease (IBD)**

Inflammatory bowel disease (IBD) is a term used to describe two chronic inflammatory conditions of the gastrointestinal tract, i.e., Crohn’s disease (CD) and ulcerative colitis (UC). They are characterized by alternate episodes of inflammation remission and recurrences that often result in intestinal fistula and stenosis [85]. The factors that affect IBD are diverse and complex and are caused by genetic-environmental interactions. Central to this response is the homeostasis between intestinal immune cells and epithelial integrity, which is composed of epithelial and mesenchymal cells [86]. Once the mucosa regenerates, microbial translocation and further inflammation are prevented [87]. TNF receptor-1 signaling in epithelial cells and Toll-like receptor activation are crucial in IBD pathogenesis; NF-κB pathways, STAT3, YAP/Notch control the regeneration of epithelial cells [88, 89].

Currently, 2 coprimary end points are used by clinicians to determine the effectiveness of therapeutic interventions in patients with Crohn’s disease (CD): symptomatic remission and endoscopic remission. There is generally a lack of accepted biomarkers to facilitate regulatory decision-making [90]. At present, FC and CRP are in clinical trials. FC is being utilized as a diagnostic, prognostic, predictive, and pharmacodynamic/response biomarker, strongly correlated with endoscopy and post-operative disease recurrence [91]. The disadvantage of CRP as a biomarker is its poor specificity and so it’s often used in combination with other markers [90]. Other CD biomarkers being explored include [90]: inflammation markers such as IL-6 IL-22, IL-23; NGAL; miR-21, miR-31, miR-146a, and miR-375; TREM-1; pASCA; Oncostatin M; microbiome markers such as lower Firmicutes; higher Faecalibacterium; OmpC, ANCA, I2, A4-Fla2, Fla-X, Cbi41; and tissue injury markers such as Pro-C4, C4M, C3M, ECM1, BGM, EL-NE, C5M, Pro-C5, MMP-3, MMP-9, MMP-14. SPP24 whose level is related to endoscopy and is significantly different before and after treatment [92]. Matrix metalloproteinase-degraded type IV collagens, Serum oncostatin M, FC and CCR9 are considered to be biomarkers of drug efficacy [93, 94], while IFN reflects disease activity [95], and the transcription signals of CD4+T and CD8+T cells are closely related to the outcome [72, 95]. Both, phase I and II clinical studies done so far show that CRP and FC biomarkers are not affected by MSCT [96]. The predictive value of these markers for MSCT prognosis and outcome therefore still needs to be experimentally verified.

Given the expression of Toll-like receptors on the surface of MSCs, Kol et al. [97] found that bacteria can promote MSC to inhibit T cell proliferation. Studies have shown that in DSS model, tail vein injection of MSC increases the number of Ki-67(+) intestinal epithelial cells, LGR5(+) intestinal stem cells and CD31(+) endothelium in mouse intestinal, which demonstrated greater recovery of intestinal epithelial integrity compared with mesalamine group [38, 41]. Compared with control group, the infiltration of F4/80+ macrophages and monocytes in the colon tissue of MSC-DSS group was reduced, and FOXP3(+) Treg increased, but the number of CD3(+) T cells did not change significantly [41].

EF mice with administration of DF-MSCs exhibited outcomes, returned to normal body weight, healed the fistulas and significantly reduced mortality and prolonged survival [98]. Intravenous or intraperitoneal or locally injection of MSC significantly down-regulated IL-17A, IL-1β, IL-6, TNF-α, IFN-γ, CD8, IL-12, SAA and chemokines, while up-regulated IL-10 and TGF-β and the expression of VEGF and Ang-2 [13, 38, 98–100]. Inflammation-related ROS and lipid peroxidation product levels decreased, and the expression of antioxidant enzymes (Catalase and SOD1 not SOD2 increased) showed the reverse pattern as oxidative stress; MSC show the capacity of inhibiting Th1 and Th17 inflammatory cells, promoting Th2 and Treg cells [13, 38, 99, 100]. A large number of studies focus only on the changes of
Perianal fistula is a serious complication of CD. MSC is a new and promising treatment for perianal fistula due to its capacity for immune regulation and tissue repair. In one study, 12 weeks after MSC local injection, 40.0%, 80.0% and 20.0% of cohort 1 [1 × 10^7 cells], 2 [3 × 10^7 cells], and 3 [9 × 10^7 cells] achieved full fistula closure [42]. And after 4 years, in cohort 2, all fistulas were closed. In this same 4 years, in cohort 1 had 63% of fistulas closed while and in cohort 3 had 43% of fistulas closed. None of the patients had detectable anti-HLA antibodies 24 weeks and 4 years after therapy [102]. Unlike in other diseases, MSCs are often transplanted directly into the patient’s fistula tissue in IBD [42, 103–105], but blood transfusion can also be used [43, 96]. In addition to complete healing of the fistula for extended period of time following local MSCT, the levels of IL-8, IL-1β and IL-6 in the fistula tissue were significantly increased; however, there was no significant difference in these factors between normal tissue and fistula tissue after MSC treatment, accompanied by decreased PDAI, MSS, PDAI and increased SIBDQ, but no change in CDAI, CRP, fibrinogen, WBC [42, 104]. We have not found the number of Treg, the levels of CRP and CF have differences before and after intravenous infusion of MSC [96], and there was no significant difference in CRP between MSCT response group and non-response group [43].

Above studies show that MSC therapy can improve the quality of life of IBD patients. Intravenous administration of MSC restores immune function in mice, promote vascular regeneration, and reduce oxidative stress. These findings still need further studies to verify. Local injection of MSC promotes healing of fistula in patients with refractory Crohn’s disease through immunosuppression and further promotes intestinal epithelial regeneration. Although CRP and CF are commonly used clinical biomarkers to reflect the disease activity of patients, evidence to support their use in MSC treatment monitoring is still lacking.

Conclusions
These studies summarized above show that the active CID is caused by an abnormal immune homeostasis that can be restored by MSCT. MSCT reduces serum inflammation-related factors TNF-α, IFN-γ, IL-1β, IL-6, IL-8, ROS levels and the number of peripheral blood Th, Tfh, and B cells, while increasing IL-10, TGF-β, IDO (a key factor in MSC immunoregulation), angiogenic factors, and the number of Treg and Breg cells. Importantly, in RA, high serum level of IFN-γ in patients before mesenchymal stem cell transplantation and the transient increase in IFN-γ after transplantation indicate that the patient can achieve better results, due to its ability to promote the release of IDO to promote MSC’s immune activity; it was also found that patients with SLE who had higher levels of baseline IFN-γ and lower levels of baseline IL-6 showed a good clinical response to MSCT. The combined use of cytokines including IFN-γ and MSC can enhance the response of patients treated with MSC, which indicates to a certain extent that patients with higher levels of cytokines in the serum treated with MSCs can achieve better results, or those who treated with these cytokines pretreated MSC may have a better effect.

Prospect
At present, there are a large number of clinical studies looking at the changes that occur in patients before and after MSCT in order to find viable indicators of treatment outcomes. It is important that multiple immune cell subgroups, cytokines and clinical features are compared between patients that respond to MSC therapy and those that do not respond so as to have a clearer understanding of which biomarkers indicate response and which ones do not. This further enables objective exploration of mechanisms by which these factors affect MSC therapy.

The indicators to be considered for the inclusion of MSC treatment patients usually include: Disease Activity Score (DAS) 28, Simple Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) for Rheumatoid arthritis (RA); SLEDAI (Urine protein and creatinine clearance should be considered for LN) for Systemic lupus erythematosus (SLE) and CD Activity Index (CDAI) score of < 250 for Crohn's disease (CD).

Treatment endpoint detection indicators often include: The remission rates of American College of Rheumatology (ACR) 20, ACR 50 and ACR 70, HAQ, RF, CRP, anticitrulline antibody for Rheumatoid arthritis (RA); British Isles Lupus Assessment Group score (BILAG), SLEDAI, Quality of life Month SF-36, Quality of life EQ-5D, Steroids dose, and Lupus serology (Alb, ANA, dsDNA, C3, C4), Renal function (GFR, BUN, urinalysis) for Systemic lupus erythematosus (SLE), and monitoring of the closure of all treated external openings that were drained at baseline to determine fluid collections > 2 cm by masked central MRI, PDAI, CDAI, IBDQ, time to combined remission, relapse and time to relapse, and van Assche score for Crohn’s disease (CD). In the future, these markers can be used as clinical indicators and biomarkers for CID patients undergoing mesenchymal stem cell therapy (MSCT).
Abbreviations
CID: Chronic inflammatory disease; MSC: Mesenchymal stem cells; hUC-MSCs: Human umbilical cord mesenchymal stem (stromal) cells; adMSCs: Adipose-derived mesenchymal stem cells; BMSC: Bone marrow-derived mesenchymal stem cells; MSCT: Mesenchymal stem cell transplantation; GvHD: Graft versus host disease; iDO: Indoleamine 2,3-dioxygenase; TGF-β: Transforming growth factor beta; PGE2: Prostaglandin E2; NO: Nitric oxide; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; IBD: Inflammatory bowel disease; PBMC: Peripheral blood mononuclear cell; SSA: Serum amyloid protein A; CRP: C reactive protein; Th: T follicular helper cells; Th: T helper cell; Breg: Regulatory B-cells; ROS: Reactive oxygen species; ALT: Alanine transaminase; ANC: Absolute neutrophil count; AST: Aspartate transaminase; BUN: Blood urea nitrogen; MTX: Methotrexate; WBC: White blood cell; VAS: Visual analogue scale; LDA: Low disease activity; LN: Lupus nephritis; P-MSCs: Placental-derived MSCs; EF: Enterocutaneous fistula; MRI: MR score of severity; PDAI: Perianal disease activity index; CD80: C80; disease activity index; AIDV: Adipose-derived stromal vascular fraction; SIBDQ: Small intestinal bowel disease questionnaire.

Acknowledgements
Not applicable.

Authors’ contributions
FFH conceived the study, collected literature and wrote the manuscript. ET collected literature and reviewed the manuscript. FJH collected literature and reviewed the manuscript. XYZ collected literature. ZW collected literature. JCT supervised the writing, offered technical review and edit of the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by the by Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (zpny2018067/cpzy2018067).

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Program and Department of Clinical Laboratory Medicine, Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
2Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China.

Received: 18 August 2021 Accepted: 4 October 2021
Published online: 08 January 2022

References
1. Straub RH, Schadrin C. Chronic inflammatory systemic diseases: an evolutionary trade-off between acutely beneficial but chronically harmful programs. Evol Med Public Health. 2016;2016(1):37–51.
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.
3. Heo JS, Choi Y, Kim HS, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37(1):115–25.
4. Kim DS, Jang IK, Lee MW, Ko YJ, Lee DH, Lee JW, Sung KW, Koo HH, Yoo RH. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ. EBioMedicine. 2018;28:261–73.
5. Liu F, Qiu H, Xue M, Zhang S, Zhang X, Xu J, Chen J, Yang Y, Xie J. MSC-secreted TGF-β regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt/FoxO1 pathway. Stem Cell Res Ther. 2019;10(1):345.
6. Zhang Z, Huang S, Wu S, Qi J, Li W, Liu S, Cong Y, Chen H, Lu L, Shi S, Wang D, Chen W, Sun L. Clearance of apoptotic cells by mesenchymal stem cells contributes to immunosuppression via PGE2. EBioMedicine. 2019;45:341–50.
7. Zhang Z, Feng R, Niu L, Huang S, Deng W, Shi B, Yao G, Chen W, Tang X, Gao X, Feng X, Sun L. Human umbilical cord mesenchymal stem cells inhibit T follicular helper cell expansion through the activation of iNOS in Lupus-Prone B6.MRL-Fas(prl) Mice. Cell Transplant. 2017;26(6):1031–42.
8. Bulati M, Mulic V, Gallo A, Amico G, Carcione C, Pampaloni M, Conaldi PG. The immunomodulatory properties of the human amnion-derived mesenchymal stromal/stem cells are induced by IFN-γ produced by activated lymphomonocytes and are mediated by cell-to-cell contact and soluble factors. Front Immunol. 2020;11:54.
9. Wu W, Xiao ZX, Zeng D, Huang F, Wang J, Liu Y, Bellanti JA, Olsen N, Zheng SG. B7–H1 promotes the functional effect of human gingiva-derived mesenchymal stem cells on collagen-induced arthritis murine model. Mol Ther. J Am Soc Gene Ther. 2020;28(11):2417–29.
10. Taechangam N, Iyer SS, Walker NJ, Arzi B, Bonjesson DL. Mechanisms utilized by feline adipose-derived mesenchymal stem cells to inhibit T lymphocyte proliferation. Stem Cell Res Ther. 2019;10(1):188.
11. Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004;13(3):263–71.
12. Petri RM, Hackel A, Aksamit A, Dumitru CA, Bruderek K, Flohe SB, Paschen A, Lang S, Brandus A. Activated tissue-resident mesenchymal stromal cells regulate natural killer cell immune and tissue-regenerative function. Stem Cell Rep. 2017;9(3):985–98.
13. Duijvestein M, Wildenberg ME, Welling MM, Hennink S, Molendijk I, Van Zuylen VL, Bosse T, Vo AS, De Jonge-Muller ES, Roelofs H, Van Der Weerd L, Verspaget HW, Bibbe WE, Te Velde AA, Van Den Brink GR, Hommes DW. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells (Dayton, Ohio). 2011;29(10):1549–58.
14. Hackel A, Aksamit A, Bruderek K, Lang S, Brandus A. TGF-α and IL-1β sensitize human MSC for IFN-γ signaling and enhance neutrophil recruitment. Eur J Immunol. 2021;51(2):319–30.
15. Wang D, Feng X, Lu L, Konkel JE, Zhang H, Chen Z, Li X, Gao X, Lu L, Shi S, Chen W, Sun L. A CDB T cell/Indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatology (Hoboken, NJ). 2014;66(8):2234–45.
16. Merlo MDF, Duhadaway JB, Montgomery JD, Peng WD, Murray PJ, Prendergast GC, Caton AJ, Muller AJ, Mandlik-Nayak L. Differential roles of IDO1 and IDO2 in T and B cell inflammatory immune responses. Front Immunol. 2016;2020:11.
17. Eleftheriadis T, Pissas G, Liakopoulos V, Stefanidis I. IDO decreases glycolysis and glutaminolysis by activating GCN2, while it increases fatty acid oxidation by activating AhR, thus preserving CD4+ T-cell survival and proliferation. Int J Mol Med. 2018;42(1):57–68.
18. Cobbold SP, Adams E, Farquhar CA, Nolan KF, Howie D, Lui PJ, Fairchild PJ, Mellor AL, Ron D, Waldmann H. Infectious tolerance via the partial roles of IDO1 and IDO2 in T and B cell inflammatory immune responses. Front Immunol. 1861;2020:11.
19. Finnerer T, Pissas G, Liakopoulos V, Stefanidis I. IDO decreases B7–H1 expression via the recruitment of mesenchymal stem cells and regulates natural killer cell immune and tissue-regenerative function. Stem Cell Res Ther. 2017;9(3):985–98.
20. Fallarino F, Grohmann U. Using an ancient tool for igniting and propa-
22. Mohammadpour H, Pourfathollah AA, Zarif MN, Tahoori MT. TNF-α modulates the immunosuppressive effects of MSCs on dendritic cells and T cells. Int Immunopharmacol. 2015;28(2):1009–17.

23. Kelly A, Houston SA, Sherwood E, Casulli J, Travis MA. Regulation of innate and adaptive immunity by TGFbeta. Adv Immunol. 2017;134:137–233.

24. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007;109(1):228–34.

25. Franquesa M, Mensah FK, Huizinga R, Strini T, Boon L, Lombardo E, Dela Rosa O, Laman JD, Grinyó JM, Weimar W, Betjes MG, Baan CC, Hoogduijn MJ. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells (Dayton, Ohio). 2015;33(3):880–91.

26. Liu R, Li X, Zhang Z, Zhou M, Sun Y, Su D, Feng X, Gao X, Shi S, Chen W, Sun L. Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis. Sci Rep. 2015;5:12777.

27. Jang E, Jeong M, Kim S, Jang K, Kang BK, Lee DY, Bae SC, Kim KS, Youn J. Infusion of human bone marrow-derived mesenchymal stem cells alleviates autoimmune nephritis in a lupus model by suppressing follicular helper T-cell development. Cell Transplant. 2016;25(1):1–15.

28. Lu K, Li HY, Yang K, Wu JL, Cai XW, Zhou Y, Li QG. Exosomes as potential alternatives to stem cell therapy for intervertebral disc degeneration: in-vitro study on exosomes in interaction of nucleus pulposus cells and bone marrow mesenchymal stem cells. Stem Cell Res Ther. 2017;8(1):108.

29. Lo S, Angela C, Reverberi D, Balli C, Ugliengo P, Principi E, Pasquali L, Becherini P, Bosco MC, Varesio L, Franzin C, Pozzobon M, Cancrerra D, Tasso R. Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization. Stem Cells Transl Med. 2017;6(5):1018–28.

30. Luz-Crawford P, Hernandez J, Djouad F, Luque-Campos N, Caicedo A, Carrére-S, Brondello JM, Vigarni ML, Frolin J, Jorgensen C. Mesenchymal stem cell reprogramming of Th17 cells is triggered by mitochondrial transfer. Stem Cell Res Ther. 2019;10(1):232.

31. Feng Z, Zhai Y, Zheng Z, Yang L, Luo X, Dong X, Han Q, Jin J, Chen Z, Zhu P. Loss of A20 in BM-MSCs regulates the Th17/Treg balance in rheumatoid arthritis. Sci Rep. 2018;8(1):427.

32. Lamas JR, Fernandez-Gutierrez B, Muñoz A, Marco F, Lopez Y, Jover JA, Abasolo L, Rodríguez-Rodríguez L. RNA sequencing of mesenchymal stem cells reveals a block of differentiation and immunomodulatory activities under inflammatory conditions in rheumatoid arthritis patients. Arthritis Res Ther. 2019;21(1):112.

33. Cheng RJ, Xiong AJ, Li YH, Pan SY, Zheng QP, Zhao Y, Liu Y, Marion TN. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. 2020;11:111.

34. Geng L, Tang X, Zhao G, Wang X, Zhao S, Zhao W, Chen G, Xiong AJ, Li YH, Pan SY, Zhang QP, Zhao Y, Liu Y, Marion TN. MicroRNA-663 induces immune response and inducing T regulatory cell phenotype. Am J Transplant Res. 2017;9(9):4149–60.

35. Sayegh S, El Atar O, Diakou K, Rauwel B, Degboe Y, Cavaignac E, Constantin A, Cantagrel A, Trak-Smaya V, Alaeddine N, Davignon J. Rheumatoid synovial fluids regulate the immunomodulatory potential of adipose-derived mesenchymal stem cells through a TNF/NF-κB-dependent mechanism. Front Immunol. 2019;10:1482.

36. Caplan HI, Olson SD, Kumar A, George M, Prabhakara KS, Wenzel P, Bedi S, Toledano-Furman NE, Tiolo F, Kamthie-Mizj J, Moell G, Cox CS. Jr. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. 2019;10:1645.

37. Soontararak S, Chow L, Johnson V, Coy J, Wheat W, Regan D, Dow S. Mesenchymal stem cells (MSC) derived from induced pluripotent stem cells (iPSC) equivalent to adipose-derived MSC in promoting intestinal healing and microbiome normalization in mouse inflammatory bowel disease model. Stem Cells Transl Med. 2018;7(6):456–67.

38. Molendijk J, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, Van Der Woude CJ, Duijvestein M, Weenaenda RA, Zwaginga JJ, Verspaget HW, Fibbe WE, Van Der Meulen-De Jong AE, Hommes DW. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2013;149(4):918–27.e6.

39. Dhere T, Copland I, Garcia M, Chiang KY, Chinnadurai R, Prasad M, Galippeau J. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease—a phase 1 trial with three doses. Aliment Pharmacol Ther. 2016;44(5):471–81.

40. Mccinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

41. Mucke J, Hoyer A, Brinks R, Bleck E, Pauly T, Schneider M, Vordenbáu- Verspaget HW, Fibbe WE, Van Der Meulen-De Jong AE, Hommes DW. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing and microbiome normalization in mouse inflammatory bowel disease model. Arthritis Res Ther. 2016;18:170.

42. Fernandes TL, Comoll AH, Lattermann C, Hernandez AJ, Bueno AF, Amano MT. Macrophage: a potential target on cartilage regeneration. Front Immunol. 2020;11:111.

43. Zheng W, Gu X, Hu D, Hao Y. Co-culture with synovial tissue in patients with rheumatoid arthritis suppress cell proliferation by regulating MAPK pathway in osteoblasts. Am J Transplant Res. 2019;11(6):3317–27.

44. Kwak SC, Cheon YH, Lee CH, Jun HY, Yoon KH, Lee MS, Kim YJ. Grape seed proanthocyanidin extract prevents bone loss via regulation of osteoclast differentiation, apoptosis, and proliferation. Nutrients. 2020;12(10):3164.

45. Takayani H. Osteoimmunology: shared mechanisms and cross-talk between the immune and bone systems. Nat Rev Immunol. 2007;7(4):292–304.

46. Singh JA, Saag KG, Bridges Jr SL, Aks EA, Bannuru RR, Sullivan MC, Vaysbrot E, Mcnaughton C, Osani M, Shanerling RH, Curtis JR, Furst DE, Parks D, Kavanagh A, Odeloff J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, Mcalinden T. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. (Hoboken, NJ). 2016;68(1):1–26.

47. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51(Suppl 6):vi5–9.

48. Finckh A, Alpizar-Rodriguez D, Roux-Lombard P. Value of biomarkers in the prevention of rheumatoid arthritis. Clin Pharmacol Ther. 2017;102(4):585–7.

49. Shin TH, Kim HS, Kang TW, Lee BC, Lee HY, Kim YJ, Shin JH, Seo Y, Won Choi S, Lee S, Shin K, Seo KW, Kang KS. Human umbilical cord blood-stem cells direct macrophage polarization and block inflammation some activation to alleviate rheumatoid arthritis. Cell Death Disease. 2016;7(12):e2524.

50. Gao J, Zhang G, Xu K, Ma D, Ren L, Fan J, Hou J, Han J, Zhang L. Bone marrow mesenchymal stem cells improve bone erosion in collagen-induced arthritis by inhibiting osteoclast-related factors and differentiating into chondrocytes. Stem Cell Res Ther. 2020;11(1):171.
55. Zhou X, Liu Z, Huang B, Yan H, Yang C, Li Q, Jin D. Orcinol glucoside et al. Stem Cell Research & Therapy (2022) 13:1
56. Xu C, Liu H, He Y, He X. Dendritic cells promote osteogenic differentiation in co-cultured with mesenchymal stem cells via the MAPK-dependent pathway. Stem Cell Res Ther. 2020;11(1):537.
57. Luo Y, Wu W, Gu J, Zhang X, Dang J, Wang J, Zheng Y, Huang F, Yuan J, Xue Y, Yu Q, Kandalam U, Celli J, Zheng SG. Human gingival tissue-derived MSC suppress osteoclastogenesis and bone erosion via CD39-adenosine signal pathway in autoimmune arthritis. EBioMedicine. 2019;43:620–31.
58. Yang Y, He X, Zhao R, Guo W, Zhu M, Xing W, Jiang D, Liu C, Xu X. Serum IFN-γ levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis. J Transl Med. 2018;16(1):165.
59. Wang D, Zhao L, Liang J, Wang J, Hua B, Feng X, Gilkeson GS, Farge D, Shi S, Sun L. A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem cell reports. 2018;10(3):537.
60. Park EH, Lim HS, Lee S, Roh K, Seo KW, Kang KS, Shin K. Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase ia clinical trial. Stem Cells Transl Med. 2018;7(8):903–12.
61. Wang L, Huang S, Li S, Li M, Shi J, Bai W, Wang Q, Zheng L, Liu Y. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase II study. Drug Des Dev Ther. 2019;13:4331–40.
62. Shadmehr S, Labibzadeh N, Emadedin M, Jaroughi N, Azimian V, Mardpour S, Hakroodi FA, Bolurieh T, Hosseini SE, Chehrazi M, Niknejad M, Baharah H, Gharibdoost F, Aghdami N. Intra-articular knee implantation of autologous bone marrow-derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: results of a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018;20(4):499–506.
63. Herndler-Brandstetter D, Flavell RA. Producing GM-CSF: a unique T helper subset? Cell Res. 2014;24(12):1379–80.
64. Lopez-Santalla M, Mancheño-Corzo P, Menta R, Lopez-Belmonte J, Delarosa O, Bueraen JA, Dalemans W, Lombardo E, Garin MI. Human adipose-derived mesenchymal stem cells modulate experimental auto-immune arthritis by modifying early adaptive T cell responses. Stem Cells (Dayton, Ohio). 2015;33(12):4933–503.
65. Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. The Lancet. 2019;393(10188):2322–43.
66. Mahajan A, Herrmann M, Muhoz LE. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol. 2016;7:35.
67. Xu S, Wang Y, Zhao M, Lu Q. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. Int Immunopharmacol. 2016;40:542–9.
68. Ma K, Du W, Wang X, Yuan S, Cai X, Liu D, Li J, Lu L. Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci. 2019;20(23):6021.
69. Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century: Rheumatology (Oxford). 2020;59(Suppl5):v4–11.
70. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Bar S, Bergeron L, Alarcon GS. Systemic lupus erythematosus: directions for systemic lupus erythematosus in adults. The Lancet. 2018;395(10230):181–203.
71. Lee JC, Lyons PA, Mckinney EF, Sverrson JM, Carr ED, Redin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011;121(10):4170–9.
72. Lin J, Yu Y, Ma J, Ren C, Chen W. PD-1–4-1CGR5–CD4+ T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology (Oxford). 2019;58(12):2188–92.
73. Tsellios K, Sarantopoulos A, Gkougkoreas I, Boura P. CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study. Clin Exp Rheumatol. 2014;32(5):630–9.
74. Myngbay B, Aboseitov V, Adilbayeva A, Assylbekov Z, Yevstratenko BP, Zhakhazanova RM, Matkarimov B, Adanichev VA, Kunz J. CTHRC1: a new candidate biomarker for improved rheumatoid arthritis diagnosis. Front Immunol. 2019;10:1353.
75. Santiago-Raber ML, Baccala R, Haraldsson KM, Choueby D, Stewart TA, Kono DH. Th1/Th17 inflammation predicts lupus-like disease in NZB mice. J Exp Med. 2005;197(6):777–88.
76. Duvvuri R, Lood C. Cell-free DNA as a biomarker in autoimmune rheumatic diseases. Front Immunol. 2019;10:502.
77. Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, Hua B, Liu B, Lu L, Gilkeson GS, Silver RM, Chen W, Shi S, Sun L. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013;22(12):2267–77.
78. Li X, Wang D, Liang J, Zhang Z, Sun L. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplant. 2013;48(4):544–50.
79. Wen L, Labopin M, Badoglio M, Wang D, Sun L, Farge-Bancel D. Prognostic factors for clinical response in systemic lupus erythematosus patients treated by allogeneic mesenchymal stem cells. Stem Cells Int. 2019;2019:7061408.
80. Wang D, Wang S, Huang S, Zhang Z, Yuan X, Feng X, Lu L, Sun L. Serum IFN-gamma predicts the therapeutic effect of mesenchymal stem cells transplantation in systemic lupus erythematosus patients. Stem Cells Transl Med. 2017;6(9):1777–85.
81. Deng D, Zhang P, Guo Y, Lim TD. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436–9.
82. Soliman S, Mohan C. Lupus nephritis biomarkers. Clin Immunol (Orlando, Fla). 2017;185:10–20.
83. Zhou T, Liao C, Li HY, Lin W, Lin S, Zhong H. Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis. Stem Cell Res Ther. 2020;11(1):48.
84. McDowell C, Farooq U, Haseeb M. Inflammatory bowel disease. Treasure Island: StatPearls Publishing; 2019.
85. Uhlig HH. Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol. 2018;36:755–81.
86. Nariris M, Coves H. Reparative inflammation takes charge of tissue regeneration. Nature. 2016;529(7586):307–15.
87. Nenciu A, Becker C, Wallaert A, Gareus R, Van Loo G, Danese S, Huth M, Nikolaeva A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446(7135):557–61.
88. Taniguchi K, Wu LW, Grivennikov SI, De Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karm M: A gg130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015;519(7541):57–62.
89. Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig N, Linggi B, Schito M, Castelle NV, Sauer JM. Biomarkers of Crohn’s disease to support the development of new therapeutic interventions. Inflamm Bowel Dis. 2020;26(10):1498–508.
90. Menees SB, Powell C, Kurlander J, Goel A. Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(4):444–54.
91. Vasinger WC, Lu K, Yau Y, Nash J, Lee J, Chang J, Paramsothy S, Kaakoush NO, Mitchell HM, Leong RW. Spp2 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for “leaky-gut” in inflammatory bowel disease. Sci Rep. 2020;10(1):12932.
mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284–91.

94. Zhou H, Xi L, Ziemek D, O'neil S, Lee J, Stewart Z, Zhan Y, Zhao S, Zhang Y, Page K, Huang A, Maciejewski M, Zhang B, Goretlick KJ, Fitz L, Pradhan V, Cataldi F, Vincent M, Von Schack D, Hung K, Hassan-Zaheae M. Molecular profiling of ulcerative colitis subjects from the TURANDOT trial reveals novel pharmacodynamic/efficacy biomarkers. J Crohn's Colitis. 2019;13(6):702–13.

95. Mckinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–6.

96. Gregoire C, Briquet A, Pirenne C, Lechanteur C, Louis E, Beguin Y. Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: a phase I-II study. Digestive Liver Disease. Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2018;50(11):1251–5.

97. Kol A, Foutouhi S, Walker NJ, Kong NT, Weimer BC, Borjesson DL. Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions. Stem Cells Dev. 2014;23(16):1831–43.

98. Hou H, Zhang L, Duan L, Liu Y, Han Z, Li Z, Cao X. Spatio-temporal metabolokinetics and efficacy of human placenta-derived mesenchymal stem/stromal cells on mice with refractory Crohn's-like enterocutaneous fistula. Stem Cell Rev Rep. 2020;16(8):1292–304.

99. Jang KJ, Lee GW, Park CH, Lee TJ, Kim JY, Sung EF, Kim SY, Jang BI, SoNG IH. Mesenchymal stem cells decrease oxidative stress in the bowels of interleukin-10 knockout mice. Gut Liver. 2020;14(1):100–7.

100. González MA, González-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136(3):978–89.

101. Chao K, Zhang S, Qiu Y, Chen X, Zhang X, Cai C, Peng Y, Mao R, Pevsner-Fischer M, Ben-Horin S, Elinaev E, Zeng Z, Chen B, He Y, Xiang AP, Chen M. Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CDS(+)B regulatory cells. Stem Cell Res Ther. 2016;7(1):109.

102. Van der Woude CJ, Molendijk I, Bonsing BA, Oosten LEM, Dijkstra G, Van Der Woude CJ, Roelen DL, Zwaginga JJ, Verspaget HW, Fibbe WE, Hommes DW, Peeters K, Van Der Meulen-De Jong AE. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas. J Crohn's Colitis. 2020;14(1):64–70.

103. De la Portilla F, Alba F, García-Olmo D, Herreras JM, González FX, Gallindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28(3):313–23.

104. Panés J, García-Olmo D, Von Assche G, Colombel JF, Reinsch W, Baumgar D, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet (London, England). 2016;388(10051):1281–90.

105. Dietz AB, Dozois EJ, Fletcher JG, Butler GW, Radel D, Lightner AL, Dave M, Friton J, Nair A, Camilleri ET, Dudakovc A, Van Wijnen AJ, Faubion WA. Autologous mesenchymal stem cells applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn's disease. Gastroenterology. 2017;153(1):59-62.e2.}

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.